Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED to Support Drug Discovery Research Using Existing Drugs as “Tool Compounds”
May 31, 2016
- G7 Leaders Vow to Consider New Incentives to Spur AMR R&D
May 30, 2016
- MHLW Panel OKs Sanofi’s PCSK9 Inhibitor on Equal Footing with Repatha
May 30, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Fail to Clear MHLW Advisory Panel
May 30, 2016
- AMED to Allocate 820 Million Yen for Measures against Antimicrobial Resistance
May 27, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- MHLW to Request Budgets to Promote Venture Companies in Response to Growth Strategy
May 26, 2016
- Pemphigoid Added to List of Clinically Significant Adverse Reactions for DPP-4 Inhibitors: Safety Bulletin
May 26, 2016
- MHLW Working Group Urges Govt to Push NTD Drug Development at Mie Summit
May 25, 2016
- MHLW to Begin Discussions this Fiscal Year on Regulation of Plasma Exports
May 25, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Added to MHLW Panel’s Review Agenda for May 27
May 24, 2016
- Takecab-Contained Blister Packs for H. pylori Eradication, Other Products to Join NHI Price List on May 25
May 24, 2016
- MHLW OKs Add’l Indications for Avastin, Other Drugs
May 24, 2016
- MHLW’s Expanded Development Request Scheme Gets Underway
May 23, 2016
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Govt’s Draft Economic Growth Strategy Embraces Use of Big Data by PMDA
May 20, 2016
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Council Determines Parathyroid Hormone Preparation for Hypoparathyroidism Has High Unmet Medical Need
May 20, 2016
- MHLW Raises Caution for Use of Harvoni, 7 Other Hep C Drugs in HBV Carriers
May 19, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…